ClinicalTrials.Veeva

Menu
Y

Yashoda Hospital | Clinical Research Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Dexamethasone
Carfilzomib
Hydroxyurea
Lyrica
Methylprednisolone
Cytarabine
Paclitaxel
Azacitidine
Dacomitinib
Atezolizumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 21 total trials

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling
Early Breast Cancer
Drug: Endocrine Therapy of Physician's Choice
Drug: Abemaciclib

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaci...

Active, not recruiting
Neoplasm Metastasis
Breast Neoplasms
Drug: Imlunestrant
Drug: Abemaciclib
Locations recently updated

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexameth...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Mezigdomide
Drug: Dexamethasone

Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the...

Enrolling
High-risk Transient Ischemic Attack
Acute Non-cardioembolic Ischemic Stroke
Drug: Asundexian (BAY2433334)
Drug: Placebo

This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and health-related quality of...

Active, not recruiting
Multiple Myeloma
Drug: Selinexor
Drug: Dexamethasone

To assess the safety and efficacy of galinpepimut-S (GPS) compared with investigator's choice of best available therapy (BAT) on overall survival (OS...

Active, not recruiting
Acute Myeloid Leukemia
Biological: Galinpepimut-S
Drug: Azacitidine

This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.

Active, not recruiting
Crohn Disease
Drug: Ozanimod
Other: Placebo

This study examines how well a new, potential medicine called NDec works and is tolerated in people with sickle cell disease. NDec is a combination o...

Enrolling
Sickle Cell Disease
Drug: HU - Hydroxyurea
Drug: Placebo

To characterize safety associated with the use of Kyprolis under the locally approved label.

Active, not recruiting
Relapsed Refractory Multiple Myeloma
Drug: Drug: Carfilzomib + Dexamethasone
Drug: Drug: Carfilzomib + Lenalidomide + Dexamethasone

Trial sponsors

Roche logo
Novo Nordisk logo
Pfizer logo
Amgen logo
Bayer logo
Biocad logo
Boehringer Ingelheim logo
Bristol-Myers Squibb (BMS) logo
Celgene logo
Karyopharm Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems